News in the treatment of hypertension and dyslipidemia

Česká verzia

Authors: Jan Václavík
Authors place of work: I. interní klinika – kardiologická LF UP v Olomouci a FN Olomouc
Published in the journal: Vnitř Lék 2017; 63(5): 333-337
Category: Reviews

Summary

These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events. A mild long-term reduction in blood pressure and LDL cholesterol has the potential to significantly reduce the lifetime risk of cardiovascular events. In the final section the article discusses options for improving patient adherence to antihypertensive and lipid treatment and the new available fixed combinations for these diseases.

Key words:
arterial hypertension – cardiovascular prevention – dyslipidemia – fixed combinations – treatment

Zdroje

1. Yusuf S, Lonn E, Pais P et al. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2032–2043. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600177>.

2. Widimský J. Komentář ke článku HOPE-3: Statins Lower CV Events in Intermediate-CHD-Risk Patients. Vnitř Lék 2016; 62(6): 474–476.

3. Yusuf S, Bosch J, Dagenais G et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2021–2031. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600176>.

4. Lonn EM, Bosch J, López-Jaramillo P et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med 2016; 374(21): 2009–2020. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1600175>.

5. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31(7): 1281–1357. Dostupné z DOI: <http://dx.doi.org/10.1097/01.hjh.0000431740.32696.cc>.

6. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315–2381. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw106>.

7. Emberson J, Whincup P, Morris R et al. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004; 25(6): 484–491.

8. Ference B, Ference T, Brook RD et al. A naturally randomized trial comparing the effect of long-term exposure to lower LDL-C, lower SBP, or both on the risk of cardiovascular disease. ESC Congr 2016. Rome: 2016. p. FP Number: 3163.

9. Jin J, Sklar GE, Min Sen Oh V et al. Factors affecting therapeutic compliance: A review from the patient’s perspective. Ther Clin Risk Manag 2008; 4(1): 269–286.

10. Fung V, Huang J, Brand R et al. Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. Clin Ther 2007; 29(5): 972–984.

11. Iskedjian M, Einarson TR, MacKeigan LD et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: evidence from a meta-analysis. Clin Ther 2002; 24(2): 302–316.

12. Chapman RH, Benner JS, Petrilla AA et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10): 1147–1152.

13. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120(8): 713–719.

14. Egan BM, Bandyopadhyay D, Shaftman SR et al. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012; 59(6): 1124–1131. Dostupné z DOI: <http://dx.doi.org/10.1161/HYPERTENSIONAHA.112.194167>.

15. Státní ústav pro kontrolu léčiv. Lipertance. Souhrn údajů o přípravku. [Internet]. 2016. Report No.: sukls288225/2016. Dostupné z WWW: <http://www.sukl.cz/modules/medication/download.php?file=SPC106789.pdf&type=spc&as=lipertance-spc>.